Bintai Kinden, IJN to collaborate on Covid-19 vaccine development


Bintai Kinden executive director Azri Azerai presenting a mock cheque to IJN director of clinical research Datuk Dr Suhaini Kadiman as the initial grant under the Bintai Healthcare-IJN Covid 19 Research Grant to fund the necessary research programmes.

KUALA LUMPUR: Bintai Kinden Corp Bhd has entered into a collaboration with Institut Jantung Negara Sdn Bhd (IJN) to develop a Covid-19 vaccine in Malaysia.

In a statement, the group said it had entered into a collaborative agreement with the national heart institute to establish a partnership in the commercial development of the Ii-Key-SARS-CoV-2 coronavirus (Covid-19) vaccine.

Get 20% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 11.12/month

Billed as RM 11.12 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 9.87/month

Billed as RM 118.40 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Malaysian palm oil glut swamps storage in top-growing state
Parkland secures approval for Main Market listing
Lynas expects one-month shutdown at Malaysian rare-earths plant
Estek invests RM20mil in new Batu Kawan manufacturing facility
Finance sector AI oversight encouraged
Malaysia's trade with BRICS nations exceeds RM846.5bil in 2025
FBM KLCI edges higher ahead of corporate results
Big Caring plans to raise RM637.8mil from Main Market IPO
Asia Pacific airlines carry 30.4mil international passengers in Sept, up 0.7% - AAPA
BMI: Asean to strengthen medicine supply chains, domestic manufacturing

Air Pollutant Index

Note: API is calculated based on 24hr running average of the most dominant parameter.

Highest API Readings

    Select State and Location to view the latest API reading

    Others Also Read